Related Experiment Video
Updated: Aug 7, 2026

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets
Published on: April 18, 2016
Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells
Yuji Tada1, Jiyang O-Wang, Yuichi Takiguchi
1Division of Pathology, Chiba Cancer Center Research Institute, Graduate School of Medicine, Chiba University, Japan.
Abstract:
Fas ligand (FasL)-expressing tumor cells are found to effectively mediate rejection of the coinoculated FasL negative parental cells while having no effect on the growth of histologically distinct tumor cells. These observations indicate that FasL induces a specific immune response against Ag derived from FasL-bearing tumors and suggest a possible role for FasL in tumor Ag presentation. Indeed, tumor cells expressing FasL can efficiently interact with dendritic cells (DCs) and this interaction requires the expression of membrane-bound FasL on tumors and Fas on DCs. Moreover, DCs cocultured with FasL-expressing tumors are able to elicit a tumor-specific immune response in vivo, suggesting that DCs acquire tumor Ag during the Fas/FasL-mediated DC-tumor contact. These results identify a novel role for FasL in augmenting tumor-DC interactions and subsequent tumor Ag acquisition by DCs, and suggest that FasL-expressing tumor cells could be used to generate tumor-specific DC vaccines.
Insights
Fas ligand (FasL)-expressing tumor cells specifically induce anti-tumor immunity by interacting with dendritic cells (DCs). This Fas/FasL interaction enhances DC uptake of tumor antigens, paving the way for novel DC vaccines.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Fas ligand (FasL) mediates tumor cell rejection.
- FasL's role in tumor antigen presentation and immune response is not fully understood.
Purpose of the Study:
- To investigate the role of FasL in tumor antigen presentation and dendritic cell (DC) interaction.
- To explore the potential of FasL-expressing tumor cells in generating tumor-specific DC vaccines.
Main Methods:
- Co-inoculation of FasL-expressing and FasL-negative tumor cells.
- Co-culture of tumor cells expressing FasL with dendritic cells (DCs).
- Assessment of DC-tumor cell interaction and subsequent immune response in vivo.
Main Results:
- FasL-expressing tumor cells mediated rejection of FasL-negative parental cells but not distinct tumor cells, indicating specificity.
- Tumor cells expressing membrane-bound FasL efficiently interacted with DCs expressing Fas.
- DCs co-cultured with FasL-expressing tumors elicited tumor-specific immune responses in vivo, demonstrating antigen acquisition.
Conclusions:
- FasL plays a novel role in enhancing tumor-DC interactions and DC-mediated tumor antigen acquisition.
- FasL-expressing tumor cells represent a promising strategy for developing tumor-specific DC vaccines.
More Related Videos
10:16Fabrication of Anisotropic Polymeric Artificial Antigen Presenting Cells for CD8+ T Cell Activation
Published on: October 12, 2018
10:35Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The Extrinsic Apoptotic Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...